Post-CDK4/6 Inhibitor Treatment: Guide to HR+/HER2- MBC ASCO 3 Mins Read Introduction to Post-CDK4/6 Inhibitor Treatment Treating hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer (MBC) has improved with CDK4/6 inhibitors like…
